Scpharmaceuticals Inc
scPharmaceuticals Inc., a pharmaceutical company, focuses on developing and commercializing products to optimize the delivery of infused therapies and patient care. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for the treatment of congestion due to fluid overload in adults with chronic heart failure and … Read more
Scpharmaceuticals Inc (SCPH) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: 0.756x
Based on the latest financial reports, Scpharmaceuticals Inc (SCPH) has a cash flow conversion efficiency ratio of 0.756x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-16.11 Million) by net assets ($-21.32 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Scpharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Scpharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Scpharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Scpharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
T3EX Global Holdings Corp
TW:2636
|
0.083x |
|
Settlebank Corporation
KQ:234340
|
0.049x |
|
FEDERAL AGRIC.N.-C.PFD D
F:A351
|
N/A |
|
Brightcom Group Limited
NSE:BCG
|
0.018x |
|
Ive Group Ltd
AU:IGL
|
0.263x |
|
DreamTech Co Ltd
KO:192650
|
0.000x |
|
Nova Technology
TWO:6613
|
0.056x |
|
Morrow Bank ASA
OL:MOBA
|
-0.029x |
Annual Cash Flow Conversion Efficiency for Scpharmaceuticals Inc (2015–2024)
The table below shows the annual cash flow conversion efficiency of Scpharmaceuticals Inc from 2015 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $13.32 Million | $-70.54 Million | -5.296x | -232.68% |
| 2023-12-31 | $37.22 Million | $-59.24 Million | -1.592x | -233.46% |
| 2022-12-31 | $72.43 Million | $-34.58 Million | -0.477x | +0.72% |
| 2021-12-31 | $56.47 Million | $-27.15 Million | -0.481x | -42.66% |
| 2020-12-31 | $82.17 Million | $-27.69 Million | -0.337x | +43.13% |
| 2019-12-31 | $51.37 Million | $-30.44 Million | -0.593x | -61.98% |
| 2018-12-31 | $78.74 Million | $-28.81 Million | -0.366x | -70.99% |
| 2017-12-31 | $106.00 Million | $-22.68 Million | -0.214x | -151.33% |
| 2016-12-31 | $-37.07 Million | $-15.46 Million | 0.417x | -21.12% |
| 2015-12-31 | $-18.24 Million | $-9.64 Million | 0.529x | -- |